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timed stimulation with interferon  
(IFN)-γ (d 0), anti-CD3 moAb OKT3 
(d 1) and interleukin (IL)-2 (from d 1 to 
the end) (8–10). The MHC-independent 
tumor-killing ability of CIK cells favors 
their possible clinical translation, as, 
in theory, they could be applied to all 
patients regardless their human leuko-
cyte antigen haplotype. CIK cells have 
a T-NK mixed phenotype with variable 
rates of CD3+CD56+ cells, considered 
mainly responsible for the antitumor 
activity (1,11,12). CIK cells express some 
activating receptors shared with natural 
killer (NK) cells such as NKG2D, DNAX 
accessory molecule-1 (DNAM-1) and 
low levels of NKp30, while they do  
not express NKp44 and NKp46, in-
hibitory killer  immunoglobulin- like 
mixed T-NK phenotype and endowed 
with wide MHC-unrestricted antitumor 
activity against both solid and hemato-
logic malignancies (1–7). CIK cells can 
be easily expanded ex vivo up to clinical 
relevant rates from circulating periph-
eral blood mononuclear cells (PBMCs), 
according to a standard protocol involving 
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receptors NKG2A and CD94 (13). 
The  antitumor activity of CIK cells is 
mainly due to the NKG2D receptor in-
tensely expressed on the membrane of 
CIK cells. The main ligands recognized 
by NKG2D are MHC class I–related mol-
ecules A and B (MIC A/B) and members 
of the unique long 16-binding proteins, 
stress-inducible proteins expressed by 
tumor cells of various origin (3,4,14–18). 
Recent clinical trials support their initial 
activity and excellent safety profile in chal-
lenging settings such as lung, renal, liver, 
breast and gastrointestinal cancers (19).
It is known that CIK cells have a pre-
dominant Th1 phenotype, with reported 
secretion of IFN-γ and tumor necrosis 
factor (TNF)-α (20,21), which are in-
volved in regulating innate and adaptive 
immunities. The other positive regula-
tory cytokines that are secreted by CIK 
cells are IL-2 and IL-4 (20,21).
Comprehensive information on the 
secretory activity of CIK cells is limited 
and needs to be more deeply explored 
to improve our knowledge of CIK cell 
biology and possible clinical applications. 
Investigation of CIK cell secretome can 
provide novel insights into its physiolog-
ical mechanisms as well as a better un-
derstanding of immunological processes 
in this context. CIK cell performance is 
positively or negatively modulated by 
both cell-to-cell interactions and soluble 
factors secreted by CIK cells themselves 
or other cells. T regulatory lymphocytes 
(Tregs) have been shown to impair CIK 
cell activity. It has been demonstrated that 
depletion of Tregs before starting the ex 
vivo culture improved CIK cell prolifera-
tion and tumor-killing activity (22). These 
effects were at least in part attributed to 
TGF-beta1 and glucocorticoid-induced 
tumor necrosis factor receptor (22). We 
hypothesize that other plasma membrane 
molecules or soluble factors have a role 
in modulation of CIK cell performance. It 
has been reported that IL-10 suppresses 
CIK cell activity and the co-culture of CIK 
cells with DC can reverse its effect (23).
In this study we explored the com-
prehensive secretory activity of patient- 
derived CIK cells, at both the protein and 
mRNA level. Furthermore, we conducted 
a dynamic analysis to highlight possible 
variations of different factors (cytokines, 
chemokines and growth factors) during 
the ex vivo expansion of CIK cells.
MaTERiaLs anD METHODs
Ex Vivo Expansion and Phenotype 
Characterization of CiK Cells
CIK cells were expanded from periph-
eral blood collected from five patients 
with histologically confirmed gastrointes-
tinal stromal tumors (GISTs) at the  
Candiolo Cancer Institute, Fondazione 
del Piemonte per L’Oncologia–IRCCS. 
All individuals provided informed con-
sent for blood donation according to a 
protocol approved by the internal review 
board and ethics committee. As control 
for the cytokines secretion analysis, we 
also generated CIK cells from five healthy 
donors. Cryopreserved PBMCs were 
seeded at a concentration of 2 × 106 cells/
mL according to the standard protocol 
(8,9), including 21 d of culture in RPMI-
1640 medium (Gibco BRL Life Technol-
ogies Italia, Monza, Italy) supplemented 
with 10% fetal bovine serum (Sigma Al-
drich, Milan, Italy), 100 U/mL penicillin 
and 100 U/mL streptomycin (Gibco BRL 
Life Technologies Italia) at 37°C and 5% 
CO2, with the timed addition of IFN-γ 
(1000 U/mL on d 0), Ab anti-CD3 OKT3 
(50 ng/mL on d 1) and IL-2 (300 U/mL  
on d 1 up to the end, refreshing the me-
dium every 2–3 d) (all factors are from 
Miltenyi Biotec, Calderara di Reno, Bolo-
gna, Italy). At d 0, a small amount of each 
PBMC culture (7 × 106) was seeded at 
the same concentration and culture con-
ditions (2 × 106 cells/mL in RPMI-1640 
medium with 10% fetal bovine serum, 
100 U/mL penicillin and streptomycin at 
37°C and 5% CO2) but without the addi-
tion of INF-γ. Aliquots of culture medium 
(4.5 mL) and 3 × 106 of PBMCs were 
collected at d 1 for quantification of cyto-
kines and RNA extraction, respectively. 
Culture medium was centrifuged to pre-
cipitate floating cells and stored at –30°C, 
while PBMCs were collected in Invitro-
gen™ TRIzol™ (Thermo Fisher Scientific, 
Milan, Italy) and stored at –80°C. The 
same procedure was repeated for each 
CIK cell culture at d 14 and 21.
The final expansion rate calculated on 
both bulk CIK cells and the CD3+CD56+ 
subset was determined. Phenotype of 
CIK cells was weekly analyzed starting 
from d 0 by standard flow cytometric 
assay. The following monoclonal anti-
bodies (mAbs) were used: CD3-FITC, 
CD4–PE, CD56-APC, CD8–PE and 
CD314-APC (anti-NKG2D) (all mAbs 
were from Miltenyi Biotec). The Miltenyi 
Biotec Treg Detection kit (CD4/CD25/
Foxp3) (APC) was used to detect T reg-
ulatory cells within CIK cultures at d 14 
and 21. Labeled cells were read on FACS 
CyAn ADP (Beckman Coulter, Cassina 
De’ Pecchi, Milan, Italy) and analyzed 
using Summit software.
Quantification of Cytokines and CiK 
Cell secretome
Cytokines released in culture medium 
by PBMCs (d 1, absence of INF-γ) and 
CIK cells (d 14 and 21) were measured 
by Bio-Plex cytokine assay (Bio-Rad 
Laboratories, Hercules, CA, USA) as 
described elsewhere (24). The Bio-Plex 
cytokine assay is designed for multi-
plexed quantitative measurement of dif-
ferent cytokines in a single well using as 
little as 50 μL of supernatants collected 
at three time points. To perform the ex-
periments, we used premixed multiplex 
beads of the Bio-Plex human cytokine 
Human 27-Plex Panel (Bio-Rad Labo-
ratories), which included 27 secreted 
proteins: cytokines, chemokines and 
growth factors (IL-1β, IL-1Ra, IL-2, IL-4, 
IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 
p70, IL-13, IL-15, IL-17, fibroblast growth 
factor [FGF]-basic, eotaxin, granulocyte 
colony-stimulating factor [G-CSF], gran-
ulocyte-macrophage colony-stimulating 
factor [GM-CSF], IFN-γ, IP-10, mono-
cyte chemoattractant protein [MCP]-1 
[MCAF], macrophage inflammatory pro-
tein [MIP]-1α, MIP-1β, platelet-derived 
growth factor [PDGF]-bb, regulated on 
activation normal T cell expressed and 
secreted [RANTES] chemokine, tumor 
necrosis factor [TNF]-α and vascular 
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significant when *p < 0.05 and highly  
significant when **p < 0.01.
All supplementary materials are available 
online at www.molmed.org.
REsULTs
Ex Vivo Expansion and Phenotype 
of CiK Cells
CIK cells were successfully generated 
from five GIST patients starting from 
cryopreserved PBMCs within 3 wks of 
culture according to a standard protocol 
that included timed addition of IFN-γ, 
Ab anti-CD3 OKT3 and IL-2 (8,9). Four 
out five patients had a diagnosis of 
advanced-stage GIST, treated with mo-
lecular targeted therapy (imatinib n = 3, 
sunitinib n = 1). One patient (PT 3) had 
localized-stage GIST, treated with surgical 
resection followed by adjuvant therapy 
with imatinib. The median expansion of 
bulk patient-derived CIK cells, calculated 
on the total CD3+ fraction, was 69-fold 
(range 12–191). The median expression 
of the CD3+CD56+ cell fraction was 34% 
(15–50). The presence of pure NK (CD3–
CD56+) cells was negligible, median 0.93% 
(0.23–3.8) at the end of the expansion. The 
subset of mature patient-derived CIK cells 
co-expressing CD3 and CD56 molecules 
(CD3+CD56+) was present with a median 
of 34% (range 15–50), whereas 74% (45–90) 
of total bulk CIK cells were CD8+. The me-
dian membrane expression of the NKG2D 
receptor on expanded patient-derived CIK 
cells was 84% (61%–96%). We confirmed 
the absence of T regulatory cells within 
CIK cultures at either d 14 or d 21 (n = 2:  
PTs 2 and 4). A summary of patient char-
acteristics and relative CIK cell expansion 
and phenotypes are reported in Table 1.
 Bioanalyzer. NanoDrop ND-1000 spec-
trophotometer was used to evaluate the 
RNA sample concentration, and 260/280 
nm and 260/230 nm ratios were consid-
ered to verify the purity of total RNA. 
For microarray analysis, we selected the 
three RNA sample pairs with the best 
RNA integrity number. Briefly, cDNA 
synthesis and biotin-labeled target syn-
thesis were performed using the Gene 
Atlas 3′ IVT Plus Reagent Kit according 
to the standard protocol supplied by 
Affymetrix. The HG-U219 Array Strip 
(Affymetrix, Santa Clara, CA, USA) hy-
bridization, staining and scanning were 
performed using the GeneAtlas platform.
Gene expression profile data were an-
alyzed with the Partek GS 6.6 software 
package and normalized using the robust 
multiarray average procedure (25). Differ-
entially expressed genes (DEGs) were then 
selected using a supervised approach with 
the analysis of variance module included 
in the Partek GS package. In particular, 
we selected all the probe sets with a fold 
change contrast ≥2 in the pairwise compar-
ison of CIK cells with PBMCs, and a false 
discovery rate (q-value) <0.05. Ingenuity 
Pathway Analysis (IPA) (www.ingenuity.
com) was used to study cellular processes 
and pathways modulated in CIK cells.
All microarray data were submitted to 
the Gene Expression Omnibus repository
(www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc = GSE97581).
statistics
Results are expressed as mean ± stan-
dard deviation. Comparisons between sam-
ples of d 14 and d 1 and between d 21 and 
d 1 were made by using  nonparametric 
unpaired t test (Mann-Whitney). Differ-
ences between groups were considered 
 endothelial growth factor [VEGF]). IL-2 
detection was included to have an inter-
nal positive control. Briefly, 50 μL of cyto-
kine standards or samples (supernatants 
from seeded cells) were incubated with 
50 μL of anti-cytokine conjugated beads 
in 96-well plates for 30 min at room tem-
perature (RT) with shaking. Plates were 
then washed three times with 100 μL of 
Bio-Plex wash buffer using the Bio-Plex 
Pro Wash Station (Bio-Rad Laboratories), 
then 25 μL of diluted detection antibody 
was added and plates were incubated 
for 30 min at RT with shaking. After 
three washes, 50 μL of streptavidin- 
phycoerythrin was added, and the plates 
were incubated for 10 min at RT with 
shaking. Finally, plates were washed 
three times, beads were suspended in 
Bio-Plex assay buffer and samples were 
analyzed on Bio-Rad 96-plate reader using 
the Bio-Plex suspension array system and 
Bio-Plex manager software (Bio-Rad Labo-
ratories) (24). Secretome of patient- derived 
CIK cells was compared with those of 
healthy donors to evaluate possible differ-
ences in the secretory pathways.
Rna Extraction and secretome Gene 
Expression Profile
Total cellular RNA was isolated from 
3 million PBMCs (d 1, absence of INF-γ) 
and CIK cells (d 14) obtained from 5 
GIST patients, using Invitrogen TRIzol 
(Thermo Fisher Scientific). We performed 
a microarray analysis of CIK cells at d 
14 instead of d 21 (mature CIK cells) to 
study gene expression changes during 
CIK cell maturation. Disposable RNA 
chips (Agilent RNA 6000 Nano Lab-
Chip kit; Agilent Technologies) were 
used to determine the purity/integrity 
of RNA samples with an Agilent 2100 
Table 1. Characteristics of patients and CIK cells.
Age/
Gender
CD3+CD56+ 
Day 0 (%)
CD3+CD56+ 
Day 14 (%)
CD3+CD56+ 
Day 21 (%)
CD3+ 
Day 21 (%)
CD3+CD8+ 
Day 21 (%)
CD3+NKG2D+ 
Day 21 (%)
Expansion 
(Fold)
PT1 59/F 3 25 40 99 81 90 119
PT2 60/M 4 10 19 98 71 76 33
PT3 64/M 7 32 34 99 59 80 68
PT4 65/M 4 9 15 99 78 82 191
PT5 66/M 5 28 33 97 76 88 81
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secretome of CiK Cells
Secretome analysis was performed at 
specific time points during the three-
week ex vivo expansion: at d 1 on PBMC 
supernatants collected after 24 h of cul-
ture in the absence of any cytokines; at 
d 14 on CIK cell cultures; and at d 21 on 
supernatants of mature CIK cells (see 
also Materials and Methods).  Figure 1 
describes the experimental design 
and shows the complete list of growth 
factors, chemokines and cytokines an-
alyzed. IL-2 detection was included to 
have an internal positive control (data 
not shown).
Mature CIK cells produced multiple 
soluble factors, including cytokines, 
chemokines and growth factors. The 
secreted proteins were schematically di-
vided based on their concentration into 
three groups: high, medium and low 
(Figure 2). We found that IL-13 (5054 ± 
2117 pg/mL), RANTES (1244 ± 642 pg/
mL), MIP-1α (1755 ± 1228 pg/mL) and 
MIP-1β (30570 ± 24613 pg/mL) were 
secreted at high levels (Figure 2A). The 
medium secreted factors were IL-1Ra 
(85 ± 9 pg/mL), IL-5 (741 ± 174 pg/mL), 
IL-8 (579 ± 228 pg/mL), IL-10 (202 ± 89 
pg/mL), IL-17 (115.5 ± 27 pg/mL), IP-10 
(518.5 ± 162 pg/mL), INF–γ (893.5 ± 172 
pg/mL), VEGF (372 ± 45 pg/mL) and 
GMCSF (174 ± 51.5 pg/mL) (Figure 2B). 
Finally, IL-1β (14 ± 4 pg/mL), IL-4  
(5 ± 1 pg/mL), IL-6 (17 ± 5 pg/mL), IL-7 
(2 ± 0.5 pg/mL), IL-9 (17 ± 4 pg/mL), 
IL-12 (8.5 ± 1 pg/mL), IL-15 (4 ± 1 pg/mL), 
eotaxin (14 ± 5 pg/mL), PDGF-bb (12 ± 
2 pg/mL), FGF basic (8 ± 4 pg/mL), 
G-CSF (6 ± 1 pg/mL) and MCP-1  
(10 ± 5 pg/mL) secreted at low levels  
(Figure 2C). The secretion pattern ob-
tained from mature patient-derived CIK 
cells (d 21) trended similarly to that ob-
served from control CIK cells generated 
from healthy donors.
To explore the dynamic of CIK cell 
secretome, the main classes of secreted 
proteins, i.e., growth factors, cytokines 
and chemokines, were analyzed at dif-
ferent time points. We compared their 
release during the ex vivo expansion at 
d 1 (as unstimulated PBMCs), d 14 and 
d 21 (mature CIK cells). We observed that 
PDGF-bb, IL-1Ra, G-CSF, IL-1β, IL-6, IL-8 
and MCP-1 were released on d 1, but their 
levels progressively and intensely de-
creased by d 14 (Figure 3A). A similar di-
minishing trend, although less pronounced, 
was observed for FGF-basic, IL-15, IL-17, 
eotaxin and RANTES (Figure 3A). On the 
contrary, the concentrations of GM-CSF, 
VEGF, IL-5, IL10 and IL-13 progressively 
increased during the ex vivo expansion of 
CIK cells (Figure 3B). The concentration 
levels of IL-4, IL-9 and IL-12 did not sig-
nificantly vary over time (Figure 3C).
secretome Gene Expression Profile 
of CiK Cells
We investigated the molecular net-
works activated during the ex vivo ex-
pansion of CIK cells. We performed gene 
expression profiling of RNA obtained 
from CIK cells collected at specific time 
points: at d 1 (basal PBMCs) and at d 14 
(CIK cells) (see Materials and Methods). 
PTs 2, 3 and 4 were selected for microar-
ray analysis based on the best RNA in-
tegrity number.
The principal component analysis 
(PCA) (Supplementary Figure S1) shows 
that the CIK cell samples clustered 
together and were clearly separated 
from PBMCs. Next, using an analysis 
of variance–based supervised approach 
to compare CIK cells with PBMCs, we 
identified 3799 DEGs. As shown in 
 Figure 4, hierarchical clustering analysis 
using the list of DEGs correctly grouped 
the different cell phenotypes. First, we 
checked the mRNA expression levels of 
27 secreted proteins analyzed by Bio-
Plex assay, and good correspondence 
between transcriptomic and proteomic 
profiles was detected. In particular, we 
confirmed upregulation of GM-CSF, IL-5, 
IL-10, IL-13 and IFN-g in mature CIK 
cells. Moreover, consistent with secre-
tome data, IL-1Ra, IL-1b, IL-6, IL-15, IL-8, 
eotaxin (CCL11) and MCP-1 were down-
regulated in mature CIK cells compared 
with PBMCs. On the contrary, PDGF-bb, 
FGF-basic, G-CSF, IL-9 and IP-10 were not 
significantly modulated (Figure 5).
Figure 1. Bio-Plex analysis and experimental design. Secretome analysis was performed 
on supernatants collected at d 1 (no cytokines), d 14 and d 21 of ex vivo expansion of 
CIK cells. The right panel shows the complete list of growth factors, chemokines and  
cytokines analyzed by Bio-Plex. IFN-γ (1000 U/mL) was added at d 0, while OKT3 antibody 
(50 ng/mL) and IL-2 (300 U/mL) were added at d 1 and up to the end, refreshing the 
 medium every 2–3 d.
R E S E A R C H  A R T I C L E
 M O L  M E D  2 3 : 2 3 5 - 2 4 6 ,  2 0 1 7  |  M E s i a n O  E T  a L .  |  2 3 9
 expansion of CIK cell precursors induced 
by in vitro treatment of PBMCs. In par-
ticular, Figure 6C shows the expression 
of genes that play a pivotal role in B 
cell apoptosis. Moreover, IPA analysis 
predicted as activated categories “cyto-
toxicity of lymphocytes,” “cytotoxicity 
of cells” and “cytotoxicity of natural 
killer cells” (Supplementary Table S3). 
In particular, genes involved in cyto-
toxic mechanism of CIK cells like NCR3/
NKp30, KLRK1/NKG2D, TRAIL/TNFSF10, 
CD226/DNAM1, CD244, CD69, CD96, 
GZMA, GZMB and PRF1 are differently 
expressed (Figure 6D).
DisCUssiOn 
Immune cells play a fundamen-
tal role against cancer; however, in 
many cases tumor cells become able 
to circumvent the activity of innate 
and adoptive immune response (26). 
NKG2D, NCR3/NKp30 and TRAIL/
TNFSF10.
Next, to identify differentially ex-
pressed pathways during CIK cell 
maturation, we performed a functional 
analysis by using IPA software (Decem-
ber 2016 release). Among inactivated 
functions in CIK cells, we found “chemo-
taxis of myeloid cells,” “phagocytosis,” 
“migration of granulocytes” and “en-
gulfment of leukocytes” (Supplementary 
Table S3).
Figure 6 shows the modulated expres-
sion of genes related to the chemotaxis 
and phagocytosis processes (panels A 
and B, respectively). Of note, functional 
gene categories “proliferation of cells,” 
“cell death of lymphocytes,” “cell death 
of mononuclear leukocytes,” “apopto-
sis of B lymphocytes” and “quantity of 
CD4+ T-lymphocytes” were activated, 
in agreement with the selection and 
Of note, among DEGs we identified 
other secreted molecules that were up-
regulated in mature patient-derived 
CIK cells, which could contribute to 
their tumor-killing activity: GZMA, 
GZMB, GZMK, PRF1, IL-32 and LTA 
(Supplementary Table S1). Furthermore, 
as shown in Supplementary Table S2, 
to better characterize the CIK cell phe-
notype, we studied the surface antigen 
expression. As expected, we found 
downregulation of several myeloid dif-
ferentiation markers (CD14, CD9, CD93, 
CSF2RA, CSF2RB, EPB41L3, receptors 
for Fc fragments of immunoglobulins, 
ITGAX, MCEMP1 and TREM1) and  
B cell antigens (CD19, CD24, CD79A, 
CXCR5 and MS4A1). Moreover, microar-
ray data confirmed upregulation in CIK 
cells of well-known surface antigens like 
CD3D, CD3G, IL-2Ra, IL-2RG, CD226/
DNAM1, ITGAL/LFA-1, KLRK1/ 
Figure 2. Secretome of mature CIK cells. Secretion of 27 cytokines and cell soluble factors were measured by Bio-Plex cytokine assay on 
CIK cell supernatants at d 21 of culture. Histograms (white for patients, black for healthy donors) represent mean values ± standard devi-
ation (pg/mL) of secreted proteins.
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Figure 3. Secretion kinetic of patient-derived CIK cells. Cell culture supernatants were collected at the indicated time points and ana-
lyzed by Bio-Plex assay. Differences between groups were considered significant when *p < 0.05 and highly significant when **p < 0.01.
Continued on the next page
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obvious impact of the study is that it 
provides a rationale to explore the func-
tional implications and possible thera-
peutic modulation of CIK secretome.
To unravel CIK secretory properties, 
we undertook a thorough investigation, 
starting from the first stages of differ-
entiation and ending at d 21, which is 
the time point of infusion of CIK cells 
in patients with cancer. We found that 
While CIK cells are usually generated 
by a standard protocol, many efforts 
are ongoing to enhance their efficacy by 
exploring new or additional cytokine in-
tegrations (33–36).
Identification of cytokines secreted 
by CIK cells during their differentiation 
sheds light on mediators that could pos-
itively or negatively modulate tumor 
growth by acting at different levels. An 
 Cancer  immunotherapy holds great po-
tential against various forms of cancer 
(27,28), exploiting either antibody or 
cell-mediated responses. Among adop-
tive immunotherapy approaches, CIK 
cells represent an intriguing therapeutic 
option, since they are endowed with 
intense MHC-independent antitumor 
activity against both hematopoietic and 
solid tumors (9,29–32).
Figure 3. Continued.
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IL-5, IL-10, IL-13, GM-CSF and VEGF 
production greatly increased during dif-
ferentiation, whereas IL-4, IL-9 and IL-12 
 cytokine secretion levels changed mini-
mally. On the contrary, IL-1β, IL-6, IL-8, 
IL-15, IL-17, eotaxin, MCP-1, IL-1Ra, 
G-CSF, FGF-basic and PDGF-bb were 
downregulated over the same time.
GM-CSF mediates a wide variety of 
effects on cells of the immune system 
(37). Although GM-CSF is among the 
growth factors known to promote the 
expansion of immunosuppressive my-
eloid-derived suppressor cells (MDSCs), 
thus promoting tumor growth and met-
astatic dissemination (38), many reports 
have also shown relevant positive effects 
of GM-CSF for immunotherapy (39,40). 
These include T cell activation, matura-
tion of dendritic cells and stimulation 
of humoral and cell-mediated responses 
(41). Data obtained in mice, using herpes 
simplex virus armed with GM-CSF, have 
shown its efficacy against pancreatic can-
cer (42). Preclinical and clinical studies 
have shown GM-CSF antitumor activity 
against melanoma, either alone or in 
association with antimelanoma vaccines 
(43,44). GM-CSF represents a success-
ful choice in association with anti-GD2 
monoclonal antibodies, also for patients 
with high-risk neuroblastoma (39).
An interesting observation from CIK 
cell secretome relates to the very low 
production of IL-6. Indeed, IL-6 is gain-
ing attention for its role in tumor biol-
ogy. It has recently been found in tissue 
samples of human prostate obtained by 
needle biopsy (45), and an integrated 
gene and miRNA expression analysis of 
prostate cancer–associated fibroblasts 
supports a prominent role for IL-6 in 
fibroblast activation (46). Moreover, IL- 
6–mediated signaling in hepatocellular 
carcinoma has been considered crucial 
for blocking initiation and malignant 
growth of this neoplastic disease by the 
anticancer agent icaritin (47). A protec-
tive role in hepatocellular carcinoma has 
been shown for chemerin, also known as 
retinoic acid receptor responder protein 
2, which inhibits IL-6 and GM-CSF ex-
pression and MDSC accumulation (48). 
Figure 4. Gene expression profile was analyzed in PBMCs (d 1) and CIK cells (d 14) 
 obtained from three GIST patients. The heat map was computed on the gene list in-
cluding 3799 DEGs using the clustering algorithm included in the Partek GS package by 
means of Euclidean distance and average linkage. Gene coloring is based on normal-
ized signals, as shown at the bottom of the figure; green indicates reduced expression, 
red increased expression. CIK cell and PBMC groups clustered separately in the dendro-
gram as shown at the top of the heat map. 
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suppress activated T cells and promote 
tumor growth (42).
Our analysis shows that human CIK 
cells secrete another crucial cytokine that 
has both positive and negative effects 
IL-6 is also among those cytokines re-
cently identified as tumor-derived fac-
tors inducing CD38 expression in ex vivo 
MDSCs. Interestingly, highly expressing 
CD38 MDSCs have an elevated ability to 
 depending on tissue context and condi-
tions. IL-10 exerts positive homeostatic ef-
fects by downmodulating global immune 
response, thus preventing tissue damage 
and chronic inflammation; however, many 
reports have shown that IL-10 impairs cy-
totoxic responses of immune cells against 
tumors (49).  Accordingly, elevated IL-10 
concentration in serum and cerebrospinal 
fluid has been linked to poor prognosis in 
different tumors (50–53), and inhibition of 
IL-10–mediated signaling increases T cell 
infiltration and responses against mouse 
tumors (54). However, recent findings 
demonstrated that IL-10 in combination 
with oncolytic virotherapy can enhance 
pancreatic cancer rejection (55).
Another cytokine playing a role in 
tumor biology is IL-13. Besides CIK 
cells, IL-13 is secreted by a variety of cell 
types, including T helper type 2 lympho-
cytes, mast cells, basophils, eosinophils, 
dendritic cells and CD8+ T lymphocytes 
(56). It is released upon stimulation by 
proteases or allergens, thus inducing 
eosinophilic inflammation and immuno-
globulin E class switching in B cells (57). 
In monocytes and macrophages, IL-13 
inhibits the production of prostaglandins, 
reactive oxygen, nitrogen intermediates 
and proinflammatory cytokines, among 
them IL-1, IL-6, IL-8, TNF-α and IL-12 
(58). It has been shown that IL-13 exerts 
multiple effects on tumor cells. Hence, it 
favors growth of cutaneous T cell lym-
phoma and its concentration increase 
correlates with the number of MDSCs in 
pancreatic, esophageal and gastric cancer. 
Accordingly, targeting of the IL13Ralpha2 
subunit of IL-13R suppresses breast cancer 
lung metastasis in mice (59,60). Our study 
shows that IL-13 is highly produced by 
CIK cells, therefore it would be worth-
while to study in depth the repercussions 
of CIK-secreted IL-13 on in vitro and in 
vivo tumor growth. Chemokines play mul-
tiple roles in cancer biology and recruit-
ment of cancer responsive immune cells. 
We also showed that CIK cells produce 
VEGF during differentiation, giving rise 
to questions on potential side effects (ie, 
favor tumor survival and dissemination). 
The role of VEGF in cancer angiogenic 
Figure 5. Gene expression profile of CIK cells and correspondence with secretome. mRNA 
expression was analyzed in PBMCs (d 1) and CIK cells (d 14). Protein levels of secreted 
proteins previously analyzed by the Bio-Plex platform were compared with the corre-
sponding mRNA expression profile. The black blocks display the mRNA expression data 
that confirm the secretome analysis results. Instead, the chess pattern displays mRNA 
 expression data that are inconsistent with secretome analysis.
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Figure 6. IPA functional analysis of gene expression data from CIK cells discovered different inhibited/activated processes based on 
the expression pattern of regulatory molecules: (A) chemotaxis, (B) phagocytosis, (C) apoptosis of B lymphocyte, (D) cytotoxicity. 
The  orange lines show that the activation effect of protein was positively confirmed by the IPA Knowledge database. The blue lines 
show that the inhibitory effect of protein was positively confirmed by the IPA Knowledge database. The gray lines indicate that the 
proteins lacked literature support to predict the activation effect. The yellow lines indicate that our results and the literature in IPA are 
not  consistent. Solid lines: direct interactions; dashed lines: indirect interactions.
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showing that it represents a powerful way 
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stimulation, thus favoring tumor meta-
static dissemination (61). Although the 
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inhibiting neoangiogenesis and metastatic 
diffusion (63,64), therefore the previously 
unknown capacity of CIK cells to secrete 
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COnCLUsiOn
In this report we analyzed the secre-
tory panel of human CIK cells laying a 
foundation for future studies on modu-
lation of CIK secretome. This will hope-
fully represent a new way to increase 
their performance against neoplastic cells 
and/or contribute to the establishment 
of a micro-environment of unfavorable 
conditions for cancer growth.
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